Drug intelligence / Profile preview

CD30 CAR-T (Hebei Senlang)

Development stage: Unknown
Lead developer: Senlang Bio
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

CD30 CAR-T (Hebei Senlang) is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target the CD30 antigen (TNFRSF8). Developed by Hebei Senlang Biotechnology, the therapy utilizes the patient's own T cells, which are genetically engineered to express a CAR specific for CD30, a protein highly expressed on the surface of malignant Reed-Sternberg cells in Hodgkin's lymphoma. Upon re-infusion, these modified T cells recognize and bind to CD30-positive cells, leading to T-cell activation, expansion, and the subsequent targeted destruction of the lymphoma cells. It is primarily being investigated for the treatment of relapsed or refractory Hodgkin's lymphoma in Phase 1/2 clinical trials.

Other names: Senl-CD30Senl-CD-30Senl-CD 30Autologous CD30-targeted CAR-T cellsCD30 CAR-TCD-30 CAR-TCD 30 CAR-T

Targets

CD30 (CD30 antigen)

Beyond the preview

Go deeper on CD30 CAR-T (Hebei Senlang).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD30 CAR-T (Hebei Senlang).

Explore the full profile